Recruiting Hereditary Transthyretin Amyloidosis Studies in Eden Prairie
About Hereditary Transthyretin Amyloidosis Clinical Trials in Eden Prairie
Hereditary transthyretin amyloidosis (hATTR) is a rare, progressive, and fatal disease caused by misfolded transthyretin protein deposits in nerves and organs. It causes polyneuropathy and cardiomyopathy. Treatment includes TTR stabilizers (tafamidis) and gene-silencing therapies (patisiran, inotersen).
There are currently 1 hereditary transthyretin amyloidosis clinical trials recruiting participants in Eden Prairie, MN. These studies are seeking a combined 52,121 participants. Research is being sponsored by AstraZeneca. Clinical trial participation is free and participants receive study-related medical care at no cost.
Hereditary Transthyretin Amyloidosis Clinical Trials in Eden Prairie — FAQ
Are there hereditary transthyretin amyloidosis clinical trials in Eden Prairie?
Yes, there are 1 hereditary transthyretin amyloidosis clinical trials currently recruiting in Eden Prairie, MN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Eden Prairie?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Eden Prairie research site will contact you about next steps.
Are clinical trials in Eden Prairie free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Eden Prairie studies also compensate for your time and travel.
What hereditary transthyretin amyloidosis treatments are being tested?
The 1 active trials in Eden Prairie are testing new therapies including novel drugs, biologics, and treatment approaches for hereditary transthyretin amyloidosis.
Data updated October 16, 2026 from ClinicalTrials.gov